{"id":"W2052266277","doi":"10.1016/j.ygyno.2009.01.012","title":"A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer","year":2009,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"ca_institutions":"Women's Health Research Institute","funders":"AstraZeneca","keywords":"Fulvestrant; Medicine; Ovarian cancer; Clinical endpoint; Internal medicine; Response Evaluation Criteria in Solid Tumors; Cancer; Oncology; Progressive disease; Phases of clinical research; Gastroenterology; Breast cancer; Toxicity; Disease; Estrogen receptor; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002539041,0.0002109502,0.0008324403,0.0001340662,0.00006186442,0.000002804498,0.0001313955,0.0001339651,0.0003085511],"category_scores_gemma":[0.00004821309,0.0001185712,0.0001413717,0.0002628344,0.00008724794,0.00002259662,0.00001388582,0.0001142863,0.00000319133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005709423,"about_ca_system_score_gemma":0.0003409419,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007873612,"about_ca_topic_score_gemma":0.00247055,"domain_scores_codex":[0.998355,0.0002387618,0.0005854359,0.0003316335,0.0001921897,0.0002969186],"domain_scores_gemma":[0.9988713,0.0003704626,0.0002584562,0.0003596838,0.00006979721,0.00007034063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.001893017,0.2276694,0.02739829,0.00001798786,0.0003032371,0.0005327417,0.01464746,0.0000528129,0.0010862,0.0002243698,0.0001564828,0.726018],"study_design_scores_gemma":[0.06429524,0.4039449,0.5142252,0.00003806773,0.0007407916,0.00002518414,0.003043641,0.00008076678,0.001280611,0.0001659606,0.01202769,0.0001318953],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906016,0.0009208978,0.000002441509,0.004773041,0.0003444203,0.002377627,0.00005198834,0.00001393074,0.0009140526],"genre_scores_gemma":[0.9975826,0.001105001,0.0002329352,0.0003387771,0.0001097409,0.0005751,0.00001215227,0.00000654,0.00003716673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7258861,"threshold_uncertainty_score":0.4835192,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05204197889891651,"score_gpt":0.3916236740312822,"score_spread":0.3395816951323657,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}